Coadministration of sofosbuvir and rilpivirine (25 mg once daily) had no effect on rilpivirine (Cmax and AUC increased by 5% and 6%, Cmin decreased by 1%). Sofosbuvir Cmax and AUC increased by 21% and 9%, whereas GS-331007 Cmax and AUC increased by 6% and 1%. No dose adjustment of sofosbuvir or rilpivirine is required when sofosbuvir and rilpivirine are used concomitantly.

The interaction between sofosbuvir and rilpivirine was evaluated in clinical trials and no dose adjustment is needed for either drug. Coadministration of rilpivirine (25 mg once daily) and sofosbuvir (400 mg single dose) was studied in 17 subjects. Sofosbuvir Cmax and AUC increased by 21% and 9%, whereas GS-331007 Cmax and AUC increased by 6% and 1%. No effect on the pharmacokinetic parameters of rilpivirine was observed.

 

Coadministration a single dose of sofosbuvir (400 mg) before and after 10 days of rilpivirine (25 mg once daily) was studied in 17 subjects. Rilpivirine modestly increased sofosbuvir exposure but had no effect on GS-331007. Sofosbuvir did not affect the pharmacokinetics of rilpivirine.